Compare Brown-Forman Corporation Class B (BF.B) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs Crispr Therapeutics AG — how do they compare? Brown-Forman Corporation Class B trades at $29.9, while Crispr Therapeutics AG trades at $53.97 (market cap $5.23B). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BF.B | CRSP | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $76.78 |
52-Week Low | $22.80 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
